Abstract
Salient features of the co-transmission by GABA and Glu in neural signaling are summarized. Experimental data have been accumulating which demonstrate; i) GABA-immunoreactivity in and GABA-release from constitutively Gluergic hippocampal mossy fibre terminals, ii) plasticity of the GABAergic phenotype of constitutively Gluergic granule cells of the Dentate Gyrus, iii) expression of GABAA receptor γ3 subunit in the mossy fibre termination zone in the CA3 subfield, iv) co-labeling of terminals for GABA and Glu in the retina, brain stem and spinal cord, and v) functional compatibility of vesicular Glu (VGLUT3) and GABA (VIAAT) transporters. It is not clear, however, whether or not Glu and GABA are released from the same terminals, and packaged in the same vesicles. Using multiple transmitters neurons may serve to reduce the metabolic cost and errors of signaling.
Keywords: Signaling by multiple transmitters, co-existence of GABA and Glu, GABAergic phenotype of dentate granule cells, co-expression of vesicular Glu and GABA transporters, varying ratios of GABA and Glu in terminals, combinatorial neural code hypothesis
Current Topics in Medicinal Chemistry
Title: Functional Significance of Co-Localization of GABA and Glu in Nerve Terminals: A Hypothesis
Volume: 6 Issue: 10
Author(s): Jozsef Somogyi
Affiliation:
Keywords: Signaling by multiple transmitters, co-existence of GABA and Glu, GABAergic phenotype of dentate granule cells, co-expression of vesicular Glu and GABA transporters, varying ratios of GABA and Glu in terminals, combinatorial neural code hypothesis
Abstract: Salient features of the co-transmission by GABA and Glu in neural signaling are summarized. Experimental data have been accumulating which demonstrate; i) GABA-immunoreactivity in and GABA-release from constitutively Gluergic hippocampal mossy fibre terminals, ii) plasticity of the GABAergic phenotype of constitutively Gluergic granule cells of the Dentate Gyrus, iii) expression of GABAA receptor γ3 subunit in the mossy fibre termination zone in the CA3 subfield, iv) co-labeling of terminals for GABA and Glu in the retina, brain stem and spinal cord, and v) functional compatibility of vesicular Glu (VGLUT3) and GABA (VIAAT) transporters. It is not clear, however, whether or not Glu and GABA are released from the same terminals, and packaged in the same vesicles. Using multiple transmitters neurons may serve to reduce the metabolic cost and errors of signaling.
Export Options
About this article
Cite this article as:
Somogyi Jozsef, Functional Significance of Co-Localization of GABA and Glu in Nerve Terminals: A Hypothesis, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323737
DOI https://dx.doi.org/10.2174/156802606777323737 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phasic Dopamine Release in Appetitive Behaviors and Drug Addiction
Current Drug Abuse Reviews Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Cell Therapy for Inner Ear Diseases
Current Pharmaceutical Design Adolescent Risk Pathways Toward Schizophrenia: Sustained Attention and the Brain
Current Topics in Medicinal Chemistry Recent Patents on Morphometric Analysis of Eukaryotic Cells
Recent Patents on Medical Imaging One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Neurodevelopmental Animal Models of Schizophrenia: Effects on Prepulse Inhibition
Current Molecular Medicine Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Histone Post-translational Modifications to Target Memory-related Diseases
Current Pharmaceutical Design Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology